• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Ulcers - Pipeline Review, H2 2012 Product Image

Ulcers - Pipeline Review, H2 2012

  • ID: 2366431
  • December 2012
  • 73 pages
  • Global Markets Direct

Ulcers – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Ulcers - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Ulcers, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ulcers. Ulcers - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Ulcers.
- A review of the Ulcers products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- READ MORE >

2
List of Tables 5
List of Figures 6
Introduction 7
REPORT COVERAGE 7
Ulcers Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Ulcers 9
Ulcers Therapeutics under Development by Companies 11
Ulcers Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Discovery and Pre-Clinical Stage Products 17
Comparative Analysis 17
Ulcers Therapeutics – Products under Development by Companies 18
Ulcers Therapeutics – Products under Investigation by Universities/Institutes 19
Companies Involved in Ulcers Therapeutics Development 20
Takeda Pharmaceutical Company Limited 20
Daewoong Pharmaceutical Co., Ltd. 21
Eisai Co., Ltd. 22
Ahn-Gook Pharmaceutical Co., Ltd. 23
Sucampo Pharmaceuticals, Inc. 24
Angelini Group 25
PLx Pharma Inc. 26
Logical Therapeutics, Inc. 27
Taiwan Liposome Company 28
Medigreen Biotechnology Corporation 29
HeliCure AB 30
Ulcers – Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Combination Products 32
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
TAK-438 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
DWJ-206 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
rabeprazole sodium ER - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
cobiprostone - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Duexis - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
naproxen etemesil - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
naproxen - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
aspirin - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 50
Celecoxib + Famotidine - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
pantoprazole - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
ambrisentan - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
alprostadil - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
naproxen + famotidine - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
MIC-31 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Helicobacter Pylori Vaccine - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Ulcers Therapeutics – Drug Profile Updates 59
Ulcers Therapeutics – Discontinued Products 63
Ulcers Therapeutics - Dormant Products 64
Ulcers – Product Development Milestones 66
Featured News & Press Releases 66
Oct 01, 2012: Horizon Pharma Announces Completion Of Sales Force Expansion 66
Sep 28, 2012: Horizon Pharma Receives Two Additional US Patent Allowances For Duexis 66
Aug 23, 2012: Pozen Provides Update On Low Dose Gastric Ulcer Drug 67
Aug 23, 2012: Pozen Provides Update On PA Program And Results Of Type A Meeting With FDA 67
Jun 22, 2012: AstraZeneca Receives Approval For Nexium In Japan For Prevention Of Recurrence Of Gastric ulcer And Duodenal Ulcer 68
Jun 22, 2012: AstraZeneca Receives Approval For Nexium In Japan For Prevention Of Recurrence Of Gastric ulcer And Duodenal Ulcer 69
Jun 20, 2012: Pozen Announces FDA Response To Phase I Bioequivalence Study Analyses Of PA32540 69
May 22, 2012: PLx Pharma Files New Drug Application For PL2200 Aspirin With FDA 70
May 20, 2012: Sucampo Presents Preclinical Data Of Cobiprostone At Digestive Disease Week 2012 70
May 19, 2012: Pozen Presents Phase I Data Of PA32540 At Digestive Disease Week 2012 71
Appendix 72
Methodology 72
Coverage 72
Secondary Research 72
Primary Research 72
Expert Panel Validation 72
Contact Us 73
Disclaimer 73

List of Tables
Number of Products Under Development for Ulcers, H2 2012 9
Products under Development for Ulcers – Comparative Analysis, H2 2012 10
Number of Products under Development by Companies, H2 2012 12
Number of Products under Investigation by Universities/Institutes, H2 2012 13
Comparative Analysis by Late Stage Development, H2 2012 14
Comparative Analysis by Mid Clinical Stage Development, H2 2012 15
Comparative Analysis by Early Clinical Stage Development, H2 2012 16
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 17
Products under Development by Companies, H2 2012 18
Products under Investigation by Universities/Institutes, H2 2012 19
Takeda Pharmaceutical Company Limited, H2 2012 20
Daewoong Pharmaceutical Co., Ltd., H2 2012 21
Eisai Co., Ltd., H2 2012 22
Ahn-Gook Pharmaceutical Co., Ltd., H2 2012 23
Sucampo Pharmaceuticals, Inc., H2 2012 24
Angelini Group, H2 2012 25
PLx Pharma Inc., H2 2012 26
Logical Therapeutics, Inc., H2 2012 27
Taiwan Liposome Company, H2 2012 28
Medigreen Biotechnology Corporation, H2 2012 29
HeliCure AB, H2 2012 30
Assessment by Monotherapy Products, H2 2012 31
Assessment by Combination Products, H2 2012 32
Assessment by Stage and Route of Administration, H2 2012 34
Assessment by Stage and Molecule Type, H2 2012 36
Ulcers Therapeutics – Drug Profile Updates 59
Ulcers Therapeutics – Discontinued Products 63
Ulcers Therapeutics – Dormant Products 64
Ulcers Therapeutics – Dormant Products (Contd..1) 65

List of Figures
Number of Products under Development for Ulcers, H2 2012 9
Products under Development for Ulcers – Comparative Analysis, H2 2012 10
Products under Development by Companies, H2 2012 11
Products under Investigation by Universities/Institutes, H2 2012 13
Late Stage Products, H2 2012 14
Mid Clinical Stage Products, H2 2012 15
Early Clinical Stage Products, H2 2012 16
Discovery and Pre-Clinical Stage Products, H2 2012 17
Assessment by Monotherapy Products, H2 2012 31
Assessment by Combination Products, H2 2012 32
Assessment by Route of Administration, H2 2012 33
Assessment by Stage and Route of Administration, H2 2012 34
Assessment by Molecule Type, H2 2012 35
Assessment by Stage and Molecule Type, H2 2012 36

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos